The shadow of generic competition has long loomed around copyright’s famous drug, Sildenafil, triggering questions about the outlook of similar pharmaceutical ventures. While first periods saw impressive returns, the intellectual property expiration has created the way for less expensive substitutes, possibly diminishing revenue and presenting a